Comparison of restenosis rate with sirolimus-eluting stent i n STEMI patients with and without diabetes at 6-month angiographic follow-up

Acta Cardiologica

Volumn 66, Issue 5, 2011, Pages 603-606

  Ma, Shuangtao ^a   Yang, Dachun ^a   Zhang, Xin ^a   Tang, Bing ^a   Li, De ^a   Sun, Meiqin ^a   Yang, Yongjian ^a  

^a General Hospital of PLA Chengdu Military Area Command   (China)

Author keywords

Diabetes; Restenosis; Sirolimus eluting stent; ST segment elevation myocardial infarction

Indexed keywords

RAPAMYCIN;

ANGIOGRAPHY; ARTICLE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; FOLLOW UP; MULTIVARIATE ANALYSIS; RESTENOSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; ANGIOPLASTY, BALLOON, CORONARY; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DIABETES COMPLICATIONS; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SIROLIMUS; SMOKING; TREATMENT OUTCOME;

EID: 80053192980     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.66.5.2131085     Document Type: Article

References (23)

1. Narayan KM, Gregg EW, Fagot-Campagna A, Engelgau MM, Vinicor F. Diabetes-a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract 2000; 50(Suppl 2): S77-84.
2. Goraya TY, Leibson CL, Palumbo PJ, Weston SA, Killian JM, Pfeifer EA, Jacobsen SJ, Frye RL, Roger VL. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol 2002; 40: 946-53.
3. Hosoi M, Sato T, Yamagami K, Hasegawa T, Yamakita T, Miyamoto M, Yoshioka K, Yamamoto T, Ishii T, Tanaka S, Itoh A, Haze K, Fujii S. Impact of diabetes on coronary stenosis and coronary artery calcification detected by electron-beam computed tomography in symptomatic patients. Diabetes Care 2002; 25: 696-701.
4. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501.
5. Chan C, Zambahari R, Kaul U, Lau CP, Whitworth H, Cohen S, Buchbinder M. A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: the DECODE study. Catheter Cardiovasc Interv 2008; 72: 591-600.
6. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Juni P. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 2008; 337: a1331.
7. Scheen AJ, Warzee F, Legrand VM. Drug-eluting stents: meta-analysis in diabetic patients. Eur Heart J 2004; 25: 2167-8.
8. Mahmud E, Bromberg-Marin G, Palakodeti V, Ang L, Creanga D, Demaria AN. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J Am Coll Cardiol 2008; 51: 2385-95.
9. Stenestrand U, James SK, Lindback J, Frobert O, Carlsson J, Schersten F, Nilsson T, Lagerqvist B. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2010; 31: 177-86.
10. Marso SP. Diabetes and drug-eluting stents: what you get and what you don't. JACC Cardiovasc Interv 2008; 1: 148-9.
11. Hoffmann R, Mintz GS. Coronary in-stent restenosis-predictors, treatment and prevention. Eur Heart J 2000; 21: 1739-49.
12. Li D, Ma S, Yang Y, Yang D, Li G, Zhang X, Zhu J, Sun M, Tang B. BTEB2 knockdown suppresses neointimal hyperplasia in a rat artery balloon injury model. Mol Med Report 2011; 4: 413-7.
13. Fogelstrand P, Mellander S, Mattsson E. Increased vascular injury reduces the degree of intimal hyperplasia following angioplasty in rabbits. J Vasc Res 2011; 48: 307-15.
14. Sick PB, Brosteanu O, Niebauer J, Hehrlein C, Schuler G. Neointima formation after stent implantation in an experimental model of restenosis: polytetrafluoroethylene-covered versus uncovered stainless steel stents. Heart Dis 2002; 4: 18-25.
15. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57: 1314-22.
16. Findeisen HM, Gizard F, Zhao Y, Qing H, Heywood EB, Jones KL, Cohn D, Bruemmer D. Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition. Arterioscler Thromb Vasc Biol 2011; 31: 851-60.
17. Ferguson JE, 3rd, Patterson C. Break the cycle: the role of cell-cycle modulation in the prevention of vasculoproliferative diseases. Cell Cycle 2003; 2: 211-9.
18. Sriram V, Patterson C. Cell cycle in vasculoproliferative diseases: potential interventions and routes of delivery. Circulation 2001; 103: 2414-9.
19. Mitra AK, Gangahar DM, Agrawal DK. Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia. Immunol Cell Biol 2006; 84: 115-24.
20. Charron T, Nili N, Strauss BH. The cell cycle: a critical therapeutic target to prevent vascular proliferative disease. Can J Cardiol 2006; 22(Suppl B): 41B-55B.
21. Hiatt BL, Ikeno F, Yeung AC, Carter AJ. Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail. Catheter Cardiovasc Interv 2002; 55: 409-17.
22. Marks AR. Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med 2003; 349: 1307-9.
23. Lorenz MC, Heitman J. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem 1995; 270: 27531-7.